High-throughput screening using patient-derived tumor xenografts to predict clinical trial drug response-Reference-Cited by-同舟云学术

High-throughput screening using patient-derived tumor xenografts to predict clinical trial drug response

Published:2015-10-19 Issue:11 Volume:21 Page:1318-1325
ISSN:1078-8956
Container-title:Nature Medicine
language:en
Short-container-title:Nat Med

Author:

Gao Hui,Korn Joshua M,Ferretti Stéphane,Monahan John E,Wang Youzhen,Singh Mallika,Zhang Chao,Schnell Christian,Yang Guizhi,Zhang Yun,Balbin O Alejandro,Barbe Stéphanie,Cai Hongbo,Casey Fergal,Chatterjee Susmita,Chiang Derek Y,Chuai Shannon,Cogan Shawn M,Collins Scott D,Dammassa Ernesta,Ebel Nicolas,Embry Millicent,Green John,Kauffmann Audrey,Kowal Colleen,Leary Rebecca J,Lehar Joseph,Liang Ying,Loo Alice,Lorenzana Edward,Robert McDonald E,McLaughlin Margaret E,Merkin Jason,Meyer Ronald,Naylor Tara L,Patawaran Montesa,Reddy Anupama,Röelli Claudia,Ruddy David A,Salangsang Fernando,Santacroce Francesca,Singh Angad P,Tang Yan,Tinetto Walter,Tobler Sonja,Velazquez Roberto,Venkatesan Kavitha,Von Arx Fabian,Wang Hui Qin,Wang Zongyao,Wiesmann Marion,Wyss Daniel,Xu Fiona,Bitter Hans,Atadja Peter,Lees Emma,Hofmann Francesco,Li En,Keen Nicholas,Cozens Robert,Jensen Michael Rugaard,Pryer Nancy K,Williams Juliet A,Sellers William R

Publisher

Springer Science and Business Media LLC

Subject

General Biochemistry, Genetics and Molecular Biology,General Medicine

Link

http://www.nature.com/articles/nm.3954.pdf

Reference52 articles.

1. Arrowsmith, J. & Miller, P. Trial watch: phase II and phase III attrition rates 2011–2012. Nat. Rev. Drug Discov. 12, 569 (2013).

2. Arrowsmith, J. Trial watch: Phase II failures: 2008–2010. Nat. Rev. Drug Discov. 10, 328–329 (2011).

3. DiMasi, J.A., Reichert, J.M., Feldman, L. & Malins, A. Clinical approval success rates for investigational cancer drugs. Clin. Pharmacol. Ther. 94, 329–335 (2013).

4. Paul, S.M. et al. How to improve R&D productivity: the pharmaceutical industry's grand challenge. Nat. Rev. Drug Discov. 9, 203–214 (2010).

5. Tentler, J.J. et al. Patient-derived tumour xenografts as models for oncology drug development. Nat. Rev. Clin. Oncol. 9, 338–350 (2012).

Cited by 1031 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Homologous Recombination Deficiency Unrelated to Platinum and PARP Inhibitor Response in Cell Line Libraries;Scientific Data;2024-02-06

2. Improving anti-cancer drug response prediction using multi-task learning on graph convolutional networks;Methods;2024-02

3. Consistency between Primary Uterine Corpus Malignancies and Their Corresponding Patient-Derived Xenograft Models;International Journal of Molecular Sciences;2024-01-25

4. Recent advances in breast cancer cell line research;International Journal of Cancer;2024-01-17

5. Optimal individualized treatment rule for combination treatments under budget constraints;Journal of the Royal Statistical Society Series B: Statistical Methodology;2024-01-10